Pseudorelapse in acute myelomonocytic leukemia after high dose methylprednisolone

Albayrak D.

Leukemia Research, vol.18, no.1, pp.61-62, 1994 (Scopus) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 1
  • Publication Date: 1994
  • Doi Number: 10.1016/0145-2126(94)90010-8
  • Journal Name: Leukemia Research
  • Journal Indexes: Scopus
  • Page Numbers: pp.61-62
  • Keywords: high dose, Leukemia, methylprednisolone, myelomonocytic, relapse
  • Ondokuz Mayıs University Affiliated: Yes


High dose methylprednisolone (HDMP) has been used both in induction treatment and in leukopenia of acute leukemia. We report the case of a 14-year-old girl with acute myelomonocytic leukemia (AMML) who developed a pseudorelapse after receiving an oral HDMP trial (30 mg/kg/day PO in the morning for 15 days) to overcome neutropenia. She presented with severe bone pain at the end of treatment. Bone marrow examination revealed 53% young promyelocytes (some with a large nucleolus), 2% myeloblast, 5% monocyte, and increased cellularity. Bone pain and promyelocytes regressed spontaneously while maintenance treatment continues. We advise that a pseudorelapse must be borne in mind after MDMP and probably GM-CSF treatments in acute leukaemias. © 1993.